Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Our purpose
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies.
Our credentials
Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange since 2016 (under symbol KURN). With additional operations in the Netherlands and the USA, we continue to grow our global team.
To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to advance bone healing.
- Listing on the SIX Swiss Exchange under the symbol KURN since 2016
- A commercial & research footprint that spans >20 markets
- Dozens of clinical and scientific expert advisers
- >25 orthobiologics-related patents
- >400 patients evaluated in Level I, randomized controlled clinical trials
- >20 well-controlled Level I-IV clinical trials initiated, including 6 that are complete1
- Published Level I evidence published in Spine
Conferences
Meet the Kuros team at our next conference and discover how our groundbreaking technology is transforming the future of bone healing. Don’t miss this chance to connect, learn, and be inspired!
26 Feb 2026
ESUBE
Sevilla, Spain
26 Feb 2026
Spine Summit
Phoenix, AZ
02 Mar 2026
AAOS
New Orleans, LA
09 Apr 2026
ISASS
Miami, FL
23 Apr 2026
CSRS Emerging Leaders
Carmel, IN
01 May 2026
AANS
San Antonio, TX
04 May 2026
EFORT
Malaga, Spain
14 May 2026
LSRS
Chicago, IL
27 May 2026
Global Spine
Istanbul, Turkey
04 Jun 2026
Footinnovate
Denver, CO
24 Jun 2026
STEGO
Cabo, Mexico
10 Sep 2026
SMISS
Las Vegas, NV
11 Sep 2026
ISSG
Las Vegas, NV
16 Sep 2026
AOFAS
Seattle, WA
23 Sep 2026
OTA
Nashville, TN
07 Oct 2026
Eurospine
Gothenburg, Sweden
07 Oct 2026
SRS
Sydney, Australia
14 Oct 2026
NASS
San Antonio, TX
06 Nov 2026
NASS Biologics
Chicago, IL
20 Nov 2026
Spine IEP
Tampa, FL
02 Dec 2026
CSRS
Austin, TX
Our Story
January 2025
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division
November 2024
Kuros Biosciences expands into extremities markets
October 2024
PRECISE Level 1 clinical trial sites activated, Launch of MagnetOs in Middle East countries
June 2024
MagnetOs Level 1 study published in Spine, MagnetOs Easypack Putty FDA cleared for standalone, extremities and pelvis
April 2024
MagnetOs Putty FDA cleared for interbody use
January 2024
MagnetOs Easypack Putty and MagnetOs Granules FDA cleared for interbody use, MagnetOs Putty FDA cleared for standalone use
November 2023
MagnetOs Flex Matrix FDA cleared for interbody use
October 2023
Chris Fair appointed CEO
August 2023
Sales distribution agreement with top 3 spine company announced
June 2023
US HQ moved to Atlanta
February 2022
MagnetOs Granules FDA cleared for standalone use
August 2021
US office opened in Boston
July 2021
First human data for MagnetOs published
July 2021
Launch of MagnetOs in nine European countries
July 2019
Signing of first APAC distributor
June 2018
First patient treated with MagnetOs (US)
February 2018
US Registration and virtual office established
January 2017
Acquired Xpand Biotechnology in 2017
to strengthen the biologics platform
May 2016
Listed on Swiss Exchange
March 2000
Founded as a spin-off of Swiss Federal Institute of Technology in Zurich
Ready to make an impact in a dynamic, international environment?
Explore our open positions and join Kuros Biosciences today!
Nothing to display.
- Wright, et al. J Bone Joint Surg Am. 2005;87(9):1909-1910.
MAT-0226